---
title: "Sunshine Biopharma files late notice for annual report for December 31, 2024"
url: "https://aibio.space/news/sunshine-biopharma-files-late-notice-annual-report-december-31-2024/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-31"
section: "Distress"
tickers: "NASDAQ:SBFM"
source: "https://www.sec.gov/Archives/edgar/data/1402328/000168316825002126/sunshine_ext.htm"
summary: "The Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results."
---

By the aibio.space news desk.

Sources

- [Sunshine Biopharma Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1402328/000168316825002126/sunshine_ext.htm)

[SBFM](https://aibio.space/companies/sunshine-biopharma/)

2025-03-31

# Sunshine Biopharma files late notice for annual report for December 31, 2024

Tickers [SBFM](https://aibio.space/companies/sunshine-biopharma/)

The Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results.

## Key facts

- **Company**: Sunshine Biopharma Inc. (NASDAQ: SBFM)

- **News type**: Distress

- **Primary source**: [Sunshine Biopharma Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1402328/000168316825002126/sunshine_ext.htm)

*The Washington Monument and the city beyond. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Sunshine Biopharma Inc. has told the Securities and Exchange Commission that it will not file its annual report for the period ended December 31, 2024 on time.

The Fort Lauderdale, Florida company filed a Form 12b-25 notice of late filing on March 31, 2025, according to the [notice](https://www.sec.gov/Archives/edgar/data/1402328/000168316825002126/sunshine_ext.htm). A Form 12b-25 lets a company claim a short extension when it cannot file a periodic report by the deadline without unreasonable effort or expense. Under the form, an annual report on Form 10-K is then due on or before the fifteenth calendar day after the original due date.

The explanation in the notice is one sentence long. It states: "The Company will need additional time to complete its financial statements."

Sunshine said all other periodic reports it was required to file during the preceding 12 months have been filed. It also answered no when asked whether it expects a significant change in results of operations from the corresponding period of the last fiscal year.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

SBFM

Sunshine Biopharma Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/sunshine-biopharma-files-late-notice-annual-report-december-31-2024/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sunshine Biopharma files late notice for annual report for December 31, 2024", 2025-03-31, https://aibio.space/news/sunshine-biopharma-files-late-notice-annual-report-december-31-2024/